Johnson Dunn Capital Advisors Inc’s Lexicon Pharmaceuticals LXRX Stock Holding History

Johnson Dunn Capital Advisors Inc’s Portfolio LXRX Stock Details LXRX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q3	$375K	Buy	+200,000	New	+$446K	0.27%	126

Other funds holding LXRX

Artal Group Luxembourg $687M AUM 17.07% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.32T AUM 44.66% 1-Year Est. Return

Siren LLC Greenwich, Connecticut $4.23B AUM 121.47% 1-Year Est. Return

State Street Boston, Massachusetts $3.44T AUM 36.12% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.92T AUM 36.1% 1-Year Est. Return

UBS Group Zurich, Switzerland $765B AUM 28.39% 1-Year Est. Return

Nuveen Charlotte, North Carolina $420B AUM 34.97% 1-Year Est. Return

Bank of New York Mellon New York $608B AUM 32.77% 1-Year Est. Return

Squarepoint New York $90.8B AUM 26.98% 1-Year Est. Return

Compagnie Lombard Odier SCmA 1204 Geneva, Switzerland $9.8B AUM 25.65% 1-Year Est. Return

Johnson Dunn Capital Advisors Inc's LXRX Position: Q3 2026 in Review

Johnson Dunn Capital Advisors Inc opened a new position in Lexicon Pharmaceuticals (LXRX) in Q3 2026: 200,000 shares worth $375K. The stake represents 0.27% of the portfolio and ranks #126 among its holdings.

87 funds tracked by Wall St. Rank hold LXRX as of Q3 2026.

Johnson Dunn Capital Advisors Inc held 200,000 shares of Lexicon Pharmaceuticals worth $375K as of Q3 2026.
Lexicon Pharmaceuticals was a new Johnson Dunn Capital Advisors Inc position in Q3 2026.
Lexicon Pharmaceuticals made up 0.27% of Johnson Dunn Capital Advisors Inc's portfolio in Q3 2026, its #126 holding.
87 funds tracked by Wall St. Rank held Lexicon Pharmaceuticals as of Q3 2026.

Based on Johnson Dunn Capital Advisors Inc's 13F filing for Q3 2026, filed 12 Nov 2026.